16,822 reports of this reaction
3.0% of all LENALIDOMIDE reports
#7 most reported adverse reaction
PLASMA CELL MYELOMA is the #7 most commonly reported adverse reaction for LENALIDOMIDE, manufactured by Celgene Corporation. There are 16,822 FDA adverse event reports linking LENALIDOMIDE to PLASMA CELL MYELOMA. This represents approximately 3.0% of all 557,894 adverse event reports for this drug.
Patients taking LENALIDOMIDE who experience plasma cell myeloma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLASMA CELL MYELOMA is a less commonly reported adverse event for LENALIDOMIDE, but still significant enough to appear in the safety profile.
In addition to plasma cell myeloma, the following adverse reactions have been reported for LENALIDOMIDE:
The following drugs have also been linked to plasma cell myeloma in FDA adverse event reports:
PLASMA CELL MYELOMA has been reported as an adverse event in 16,822 FDA reports for LENALIDOMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLASMA CELL MYELOMA accounts for approximately 3.0% of all adverse event reports for LENALIDOMIDE, making it a notable side effect.
If you experience plasma cell myeloma while taking LENALIDOMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.